A Mab A Case Study In Bioprocess Development _hot_ May 2026
The A-MAb Case Study is a landmark document in biopharmaceutical development, created by the CMC Biotech Working Group (a collaboration of major companies including Pfizer, Amgen, and GSK) to illustrate how Quality by Design (QbD) principles can be applied to monoclonal antibodies. 1. Core Purpose and Framework
The development of a monoclonal antibody (mAb) bioprocess is a complex and challenging task. Monoclonal antibodies are a class of therapeutic proteins used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The bioprocess development of a mAb involves several critical steps, including cell line development, fermentation, purification, and formulation. In this case study, we will explore the bioprocess development of a model mAb, "A Mab," from cell line development to commercial-scale production. A Mab A Case Study In Bioprocess Development
The initial bioprocess for mAb-A production involved a traditional approach: The A-MAb Case Study is a landmark document
3.2 Capture Chromatography (Protein A)
- Resin: MabSelect PrismA (Cytiva)
- Load: Clarified harvest (5.0 g/L titer, 10–15 g mAb/L resin)
- Elution: 100 mM sodium acetate, pH 3.5
- Yield: 95%, HCP reduced from 250,000 ppm → 800 ppm.
2. Upstream Development: Taming the Cell Line
The Problem
Initial transient expression showed promising titers (3.2 g/L) but unacceptable levels of high molecular weight (HMW) aggregates (15%) and host cell protein (HCP) release upon cell lysis. pH 3.5 Yield: 95%
It outlines a systematic approach to identifying which product attributes (like glycosylation or aggregation) significantly impact safety and efficacy. Upstream Manufacturing Development:
